OrganOx Secures $142 Million in Equity Financing to Advance Metra Platform
Deal News | Feb 24, 2025 | HealthQuest Capital Management
OrganOx Ltd., a prominent player in the organ medical technology sector, has announced the completion of a $142 million equity financing round to support the advancement of its groundbreaking metra platform. This funding effort, led by HealthQuest Capital, saw significant participation from both new and existing investors including BGF, Lauxera Capital Partners, Sofina, Soleus Capital, and Avidity Partners. The oversubscribed equity round is set to enhance OrganOx's capability to lead in the organ technology market by utilizing the metra platform for liver and kidney transplants—enabling better organ preservation and assessment before transplant. Operational in major territories like the U.S., Europe, Canada, and Australia, the metra technology has been used in over 5,000 liver transplants, showcasing its efficacy and potential. The company is poised to expand its services and introduce its technology into clinical trials for kidney use and potential applications in the management of liver failures with genetically engineered porcine organs. Guided by significant investments and strategic partnerships, OrganOx is committed to addressing the critical need for advanced organ medical solutions.
Sectors
- Healthcare Technology
- Biotechnology
- Private Equity & Venture Capital
Geography
- United Kingdom – OrganOx is based in Oxford, England, indicating its roots in the UK.
- United States – HealthQuest Capital, the leading investor in the funding round, is based in Madison, New Jersey, USA.
- Global – The metra technology is approved in several key markets including the U.S., Europe, Canada, and Australia, demonstrating OrganOx's global presence.
Industry
- Healthcare Technology – The article focuses on OrganOx's technology for organ preservation and transplant, a critical innovation in healthcare technology.
- Biotechnology – OrganOx's development of normothermic machine perfusion and collaboration with genetically engineered organs highlights advancements in biotechnology.
- Private Equity & Venture Capital – The financing round led by HealthQuest Capital involves investments from various venture capital and private equity firms.
Financials
- $142 million – Total amount raised by OrganOx in the equity financing round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| OrganOx Ltd. | Target Company | Company | An organ medical technology company known for its metra platform. |
| HealthQuest Capital | Bidding Company/Investor | Company | A new investor leading the $142 million equity financing round. |
| BGF | Investor | Company | An existing investor in OrganOx participating in the current funding round. |
| Lauxera Capital Partners | Investor | Company | An existing investor joining the funding round. |
| Sofina | Investor | Company | A new investor in the equity financing round. |
| Soleus Capital | Investor | Company | A new investor in the equity financing round. |
| Avidity Partners | Investor | Company | A new investor participating in the equity financing round. |
| Piper Sandler | Financial Advisor | Company | Acted as the exclusive financial advisor to OrganOx for the transaction. |
| Latham & Watkins | Legal Advisor | Company | Served as legal counsel to OrganOx during the transaction. |
| eGenesis, Inc. | Partner | Company | Collaborates with OrganOx on potential studies involving genetically engineered organs. |